Inhibition of poly(ADP-ribose) polymerase in cancer
Copyright policy )Inhibition of poly(ADP-ribose) polymerase in cancer
Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.
- Newcastle University United Kingdom
- University of Newcastle Australia Australia
Clinical Trials as Topic, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, Combined Modality Therapy, Neoplasms, Animals, Humans, Drug Therapy, Combination, Enzyme Inhibitors, Poly(ADP-ribose) Polymerases
Clinical Trials as Topic, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, Combined Modality Therapy, Neoplasms, Animals, Humans, Drug Therapy, Combination, Enzyme Inhibitors, Poly(ADP-ribose) Polymerases
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).102 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!